# Bilaterality in papillary thyroid carcinoma: long-term outcomes and predictive factors

**Authors:** Jingwen Zhang, Mengjia Fei, Wenhan Wang, Yijie Dong, Jianqiao Zhou

PMC · DOI: 10.1186/s13044-026-00285-8 · 2026-01-12

## TL;DR

This study examines how bilaterality in papillary thyroid carcinoma affects long-term outcomes and identifies risk factors that predict its occurrence.

## Contribution

The study identifies specific predictive factors for bilaterality in papillary thyroid carcinoma and evaluates its impact on recurrence-free survival.

## Key findings

- Bilaterality in PTC is significantly associated with shorter recurrence-free survival.
- Multifocality, advanced N stage, obesity, and family history of thyroid cancer are independent predictors of bilaterality.
- Patients with bilaterality require intensive postoperative follow-up to monitor recurrence.

## Abstract

Bilaterality in papillary thyroid carcinoma (PTC) is a critical factor influencing surgical approach selection. This study aimed to investigate the long-term outcomes and predictive factors associated with bilaterality in PTC.

This retrospective study reviewed 2,816 consecutive PTC patients who underwent total thyroidectomy between January 2013 and December 2015. Risk factors for bilaterality were analyzed using multivariate logistic regression. Among these, 1282 patients with ≥ 24-months follow-up were included in further recurrence/persistence analysis. The primary outcome measured was recurrence-free survival (RFS).

Bilaterality was significantly associated with shorter RFS compared to unilateral PTC (p < 0.01), with a mean follow-up of 74.3 ± 33.3 months (median: 71 months; range: 24–140 months). Additionally, multifocality (OR = 4.58, p < 0.01), advanced N stage (N1a: OR = 1.36, p = 0.002; N1b: OR = 1.61, p < 0.01), obesity (OR = 1.74, p < 0.01), and a family history of thyroid cancer (OR = 2.16, p < 0.01) were independent predictors of bilaterality.

A comprehensive preoperative examination should be conducted to detect bilaterality, particularly in PTC patients with identified risk factors. Additionally, intensive postoperative follow-up is recommended for patients with bilaterality to monitor for recurrence/persistence.

## Linked entities

- **Diseases:** papillary thyroid carcinoma (MONDO:0005075), thyroid cancer (MONDO:0002108)

## Full-text entities

- **Genes:** TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TG (thyroglobulin) [NCBI Gene 7038] {aka AITD3, TGN}
- **Diseases:** follicular (MESH:D005497), FNMTC (MESH:C536911), Tumor (MESH:D009369), Hashimoto's thyroiditis (MESH:D050031), nodal (MESH:D013611), PTC (MESH:D000077273), TRP (MESH:D001932), LNM (MESH:D008207), obesity (MESH:D009765), hyperinsulinemia (MESH:D006946), differentiated thyroid cancer (MESH:D013964), medullary, or anaplastic carcinoma (MESH:D002277), inflammatory (MESH:D007249), N (MESH:C536108), Thyroid (MESH:D013966), metastases (MESH:D009362)
- **Chemicals:** iodine-131 (MESH:C000614965), TSH (MESH:D013972)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V600E

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12797911/full.md

---
Source: https://tomesphere.com/paper/PMC12797911